Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab570
Abstract: OBJECTIVE To estimate the occurrence and relative risks of first ever incident non-cutaneous cancer overall and by 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment… read more here.
Keywords: clinical practice; targeted synthetic; treatment; rheumatology ... See more keywords
Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Sign Up to like & getrecommendations! Published in 2023 at "PLoS computational biology"
DOI: 10.1371/journal.pcbi.1011073
Abstract: Cycling of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control. We aimed to assess and validate treatment response… read more here.
Keywords: biologic targeted; rheumatoid arthritis; deep learning; targeted synthetic ... See more keywords